Phase III study of atezolizumab added to paclitaxel in the first-line treatment of metastatic triple-negative breast cancer (IMpassion131) fails to meet primary endpoint

The addition of atezolizumab to paclitaxel failed to improve progression-free survival (versus placebo plus paclitaxel) in the PD-L1-positive population (primary endpoint). Overall survival follow-up (secondary endpoint) is planned to continue until the final analysis.


Biospace Inc.